[Successful management of recurrent bleeding with tocilizumab in an acquired hemophilia A patient with rheumatoid arthritis]

Rinsho Ketsueki. 2017;58(7):738-742. doi: 10.11406/rinketsu.58.738.
[Article in Japanese]

Abstract

A 61-year-old woman with rheumatoid arthritis was diagnosed as having acquired hemophilia A with extensive subcutaneous bleeding. The patient was treated with a corticosteroid, and her symptoms improved temporarily. However, these recurred during the tapering of her corticosteroid dose, and neither the re-increase in the dose nor the addition of cyclophosphamide could control her bleeding tendency. After the administration of an anti-IL-6 receptor antibody (tocilizumab), the doses of corticosteroid and cyclophosphamide could be tapered. Tocilizumab combined with another immunosuppression therapy might be effective in the treatment of acquired hemophilia A.

Keywords: Acquired hemophilia A; Anti-IL-6 receptor antibody; Rheumatoid arthritis.

Publication types

  • Case Reports

MeSH terms

  • Adrenal Cortex Hormones / administration & dosage
  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Arthritis, Rheumatoid / etiology*
  • Cyclophosphamide / administration & dosage
  • Drug Combinations
  • Female
  • Hemophilia A / complications
  • Hemophilia A / drug therapy*
  • Hemorrhage / etiology*
  • Humans
  • Middle Aged
  • Recurrence

Substances

  • Adrenal Cortex Hormones
  • Antibodies, Monoclonal, Humanized
  • Drug Combinations
  • Cyclophosphamide
  • tocilizumab